Heil German Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-11-2024
- Paid Up Capital ₹ 0.10 M
as on 17-11-2024
- Company Age 14 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2023)
- Ebitda
- Net Worth
- Total Assets 0.46%
(FY 2023)
About Heil German Pharmaceuticals
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Bhupendra Kukreja and Sanjay Cheturam serve as directors at the Company.
- CIN/LLPIN
U24239MH2010PTC209694
- Company No.
209694
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Nov 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Heil German Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhupendra Kukreja  | Director | 01-Nov-2010 | Current |
| Sanjay Cheturam | Director | 01-Nov-2010 | Current |
Financial Performance and Corporate Structure Insights of Heil German Pharmaceuticals.
Heil German Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Heil German Pharmaceuticals?
In 2023, Heil German Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Adroit Pharmaceuticals Private LimitedActive 47 years 7 monthsBhupendra Kukreja and Sanjay Cheturam are mutual person
- Household Pharmaceuticals LimitedActive 30 years 9 months
Bhupendra Kukreja and Sanjay Cheturam are mutual person
- Haseeb Pharmaceuticals Private LimitedActive 25 years 8 months
Bhupendra Kukreja and Sanjay Cheturam are mutual person
- Leela Organics Private LimitedActive 4 years 2 months
Bhupendra Kukreja and Sanjay Cheturam are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Heil German Pharmaceuticals?
Unlock and access historical data on people associated with Heil German Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Heil German Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Heil German Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
